Addendum
Pembrolizumab (non-squamous NSCLC, combination chemotherapy) - Addendum to commission A19-30
Report documents
-
Addendum
Pembrolizumab (non-squamous NSCLC, combination chemotherapy) - Addendum to commission A19-30
Dossier assessment
First-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no EGFR or ALK positive mutations
PD-L1 expression < 50%: proof of major added benefit for women, indication of minor added benefit for men. PD-L1 expression ≥ 50%: hint of major added benefit for women, hint or lesser benefit for men
Press releases
Pembrolizumab in metastatic NSCLC: now added benefit for subpopulations
Additional information
Federal Joint Committee (G-BA)
2019-09-19 A G-BA decision was published.
Project details
- Project no.
- A19-61
- Commission
- Commission awarded on 05.08.2019 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Pembrolizumab (non-squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed